Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment

We sought to evaluate the within‐drug benefit‐risk of olanzapine long‐acting injection (LAI) using both quantitative and qualitative methods. Subjects included 1192 adult patients with schizophrenia or schizoaffective disorder who participated in clinical trials with the opportunity for at least two...

Descripción completa

Detalles Bibliográficos
Autores principales: Detke, Holland C., Lauriello, John, Landry, John, McDonnell, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311440/
https://www.ncbi.nlm.nih.gov/pubmed/24996038
http://dx.doi.org/10.1002/mpr.1443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311440/
https://www.ncbi.nlm.nih.gov/pubmed/24996038
http://dx.doi.org/10.1002/mpr.1443

Ejemplares similares